Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Navigation/Suche
- Forscher*innen
- Institutionen
- Projekte
- Publikationen
- Partner
- Geldgeber
- Ausstattung
- Knowhow
- Forschungsfelder
"Köpfe" der aktuellen Meldungen:
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Grammer, T; Kleber, M; Silbernagel, G; Scharnagl, H; März, W.
[Residual risk: The roles of triglycerides and high density lipoproteins].
Dtsch Med Wochenschr. 2016; 141(12):870-877
Doi: 10.1055/s-0042-104049
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- März Winfried
- Scharnagl Hubert
- Silbernagel Günther
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- In clinical trials, the reduction of LDL-cholesterol (LDL-C) with statins reduces the incidence rate of cardiovascular events by approximately one third. This means, that a sizeable "residual risk" remains. Besides high lipoprotein (a), disorders in the metabolism of triglyceride-rich lipoproteins and high density liproteins have been implicated as effectors of the residual risk. Both lipoprotein parameters correlate inversely with each other. Therefore, the etiological contributions of triglycerides and / or of HDL for developing cardiovascular disease can hardly be estimated from either observational studies or from intervention studies. The largely disappointing results of intervention studies with inhibitors of the cholesteryl ester transfer protein and in particular the available set of genetically-epidemiological studies suggest that in the last decade, the importance of HDL cholesterol has been overvalued, while the importance of triglycerides has been underestimated. High triglycerides not always atherogenic, but only if they are associated with the accumulation relatively cholesterol-enriched, incompletely catabolized remnants of chylomicrons and very low density lipoproteins (familial type III hyperlipidemia, metabolic syndrome, diabetes mellitus). The normalization of the concentration of triglycerides and remnants by inhibiting the expression of apolipoprotein C3 is hence a new, promising therapeutic target. © Georg Thieme Verlag KG Stuttgart · New York.
- Find related publications in this database (using NLM MeSH Indexing)
- Cardiovascular Diseases - blood
- Cardiovascular Diseases - prevention & control
- Cholesterol, HDL - blood
- Cholesterol, LDL - blood
- Drug Therapy, Combination -
- Fibric Acids - adverse effects
- Fibric Acids - therapeutic use
- Humans -
- Hypercholesterolemia - blood
- Hypercholesterolemia - complications
- Hypercholesterolemia - drug therapy
- Hypertriglyceridemia - blood
- Hypertriglyceridemia - complications
- Hypertriglyceridemia - drug therapy
- Hypolipidemic Agents - therapeutic use
- Niacin - adverse effects
- Niacin - therapeutic use
- Risk Factors -
- Triglycerides - blood